Platelet activation and the protective effect of aprotinin in hepatolithiasis patients.
OBJECTIVE
To explore platelet activation and the protective effect of aprotinin in patients with hepatolithiasis.


METHODS
The count of platelets and levels of CD62P and CD63 were measured by flow cytometry in 38 patients with hepatolithiasis. Several measurements were carried out after treatment with aprotinin.


RESULTS
The levels of CD62P, CD63 in patients with hepatolithiasis were higher than those in patients with cholecystolithiasis (P<0.05), but the count of platelets was lower (P<0.05). After operation, the levels of CD62P, CD63 were significantly increased in patients with hepatolithiasis, but the count of platelets was lower (P<0.05). Postoperative levels of CD62P, CD63 were significantly lower in patients treated with aprotinin than in normal controls (P<0.05); but there was no significant change in the count of platelets in the two groups.


CONCLUSIONS
Platelet activation occurs in patients with hepatolithiasis, and may be inhibited by aprotinin.
Feng
Wen-Ming
WM
Department of Hepatobiliary Surgery, First Hospital of Huzhou, Huzhou 313000, China. d_fwm@hotmail.com
Bao
Ying
Y
Fei
Mao-Yun
MY
Chen
Qiu-Qiang
QQ
Yang
Qi
Q
Dai
Chuang
C
D000328:Adult; D000368:Aged; D007611:Aprotinin / Q000627:therapeutic use*; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D002763:Cholecystectomy / Q000379:methods*; D042883:Choledocholithiasis / Q000175:diagnosis / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D015539:Platelet Activation; D010976:Platelet Count; D011300:Preoperative Care / Q000379:methods; D011336:Probability; D012016:Reference Values; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
D007611:Aprotinin